NASDAQ:AVDL

Avadel Pharmaceuticals Stock Forecast, Price & News

$5.17

-0.19 (-3.54 %)

(As of 10/20/2020 12:00 AM ET)

Add

Compare

Today's Range

$5.04

Now: $5.17▼

$5.40

50-Day Range

$5.02

MA: $5.69▼

$7.31

52-Week Range

$3.41

Now: $5.17▼

$13.49

Volume414,999 shs

Average Volume812,885 shs

Market Capitalization$301.00 million

P/E Ratio32.31

Dividend YieldN/A

Beta1.32

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.56, Avadel Pharmaceuticals has a forecasted upside of 220.4% from its current price of $5.17.
Amount of Analyst Coverage
Avadel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Avadel Pharmaceuticals has received 284 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Avadel Pharmaceuticals has received 298 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Avadel Pharmaceuticals has received 51.20% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote “Outperform” if you believe AVDL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Avadel Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Avadel Pharmaceuticals does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avadel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,018,779.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.41% of the stock of Avadel Pharmaceuticals is held by insiders.
Percentage Held by Institutions
96.86% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Avadel Pharmaceuticals are expected to decrease in the coming year, from ($0.68) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avadel Pharmaceuticals is 32.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 19.15.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avadel Pharmaceuticals is 32.31, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.01.

Overall Beat the Market Rank^™

1.98 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:AVDL

Previous Symbol

CUSIPN/A

CIK1012477

Webwww.avadel.com

Phone011-1-485-1200

Employees144

Debt

Debt-to-Equity Ratio0.69

Current Ratio10.25

Quick Ratio10.25

Price-To-Earnings

Trailing P/E Ratio32.31

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$59.22 million

Price / Sales5.08

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.78) per share

Price / Book-6.63

Profitability

EPS (Most Recent Fiscal Year)($0.89)

Net Income$-33,230,000.00

Net Margins38.70%

Return on Equity-69.24%

Return on Assets-12.78%

Miscellaneous

Outstanding Shares58,221,000

Market Cap$301.00 million

Next Earnings Date11/10/2020 (Estimated)

OptionableOptionable

$5.17

-0.19 (-3.54 %)

(As of 10/20/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

How has Avadel Pharmaceuticals' stock been impacted by COVID-19?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AVDL stock has decreased by 35.3% and is now trading at $5.17.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Avadel Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avadel Pharmaceuticals.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Avadel Pharmaceuticals.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The company earned $10.09 million during the quarter, compared to analysts' expectations of $8.08 million. Avadel Pharmaceuticals had a net margin of 38.70% and a negative return on equity of 69.24%.
View Avadel Pharmaceuticals' earnings history.

What price target have analysts set for AVDL?

8 Wall Street analysts have issued 12-month price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $13.50 to $22.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $16.56 in the next twelve months. This suggests a possible upside of 220.4% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 4,040,000 shares, a decline of 36.2% from the September 15th total of 6,330,000 shares. Based on an average trading volume of 845,300 shares, the short-interest ratio is currently 4.8 days.
View Avadel Pharmaceuticals' Short Interest.

Who are some of Avadel Pharmaceuticals' key competitors?

Some companies that are related to Avadel Pharmaceuticals include Mersana Therapeutics (MRSN), Kiniksa Pharmaceuticals (KNSA), Theravance Biopharma (TBPH), Applied Molecular Transport (AMTI), Cytokinetics (CYTK), Nabriva Therapeutics (NBRV), NGM Biopharmaceuticals (NGM), Zogenix (ZGNX), Phathom Pharmaceuticals (PHAT), Karyopharm Therapeutics (KPTI), Constellation Pharmaceuticals (CNST), Retrophin (RTRX), Indivior (INVVY), Supernus Pharmaceuticals (SUPN) and Generation Bio (GBIO).
View all competitors.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods plc (ABF.L) (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:

Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Investors Asset Management of Georgia Inc. GA ADV (0.09%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends for Avadel Pharmaceuticals.

Which major investors are buying Avadel Pharmaceuticals stock?

AVDL stock was acquired by a variety of institutional investors in the last quarter, including Investors Asset Management of Georgia Inc. GA ADV. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, and Thomas S Mchugh.
View insider buying and selling activity for Avadel Pharmaceuticals.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $5.17.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $301.00 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is www.avadel.com.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings